PMID- 29460393
OWN - NLM
STAT- MEDLINE
DCOM- 20190506
LR  - 20231112
IS  - 2472-1727 (Electronic)
VI  - 110
IP  - 10
DP  - 2018 Jun 1
TI  - Embryo-fetal development studies with the dietary supplement vinpocetine in the 
      rat and rabbit.
PG  - 883-896
LID - 10.1002/bdr2.1207 [doi]
AB  - Dietary supplement and natural product use is increasing within the United 
      States, resulting in growing concern for exposure in vulnerable populations, 
      including young adults and women of child-bearing potential. Vinpocetine is a 
      semisynthetic derivative of the Vinca minor extract, vincamine. Human exposure to 
      vinpocetine occurs through its use as a dietary supplement for its purported 
      nootropic and neuroprotective effects. To investigate the effects of vinpocetine 
      on embryo-fetal development, groups of 25 pregnant Sprague-Dawley rats and 8 
      pregnant New Zealand White rabbits were orally administered 0, 5, 20, or 60 mg 
      vinpocetine/kg and 0, 25, 75, 150, or 300 mg/kg daily from gestational day (GD) 
      6-20 and GD 7-28, respectively. Pregnant rats dosed with vinpocetine demonstrated 
      dose-dependent increases in postimplantation loss, higher frequency of early and 
      total resorptions, lower fetal body weights, and fewer live fetuses following 
      administration of 60 mg/kg, in the absence of maternal toxicity. Additionally, 
      the rat fetuses displayed dose-dependent increases in the incidences of 
      ventricular septum defects and full supernumerary thoracolumbar ribs. Similarly, 
      albeit at higher doses than the rats, pregnant rabbits administered vinpocetine 
      displayed an increase in postimplantation loss and fewer live fetuses (300 
      mg/kg), in addition to significantly lower fetal body weights (>/=75 mg/kg). In 
      conclusion, vinpocetine exposure resulted in similar effects on embryo-fetal 
      development in the rat and rabbit. The species differences in sensitivity and 
      magnitude of response is likely attributable to a species difference in 
      metabolism. Taken together, these data suggest a potential hazard for pregnant 
      women who may be taking vinpocetine.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Catlin, Natasha
AU  - Catlin N
AUID- ORCID: 0000-0002-8100-0701
AD  - Division of the National Toxicology Program, National Institute of Environmental 
      Health Sciences, Research Triangle Park, North Carolina.
FAU - Waidyanatha, Suramya
AU  - Waidyanatha S
AD  - Division of the National Toxicology Program, National Institute of Environmental 
      Health Sciences, Research Triangle Park, North Carolina.
FAU - Mylchreest, Eve
AU  - Mylchreest E
AD  - Southern Research Institute, Birmingham, Alabama.
FAU - Miller-Pinsler, Lutfiya
AU  - Miller-Pinsler L
AD  - Southern Research Institute, Birmingham, Alabama.
FAU - Cunny, Helen
AU  - Cunny H
AD  - Division of the National Toxicology Program, National Institute of Environmental 
      Health Sciences, Research Triangle Park, North Carolina.
FAU - Foster, Paul
AU  - Foster P
AD  - Division of the National Toxicology Program, National Institute of Environmental 
      Health Sciences, Research Triangle Park, North Carolina.
FAU - Sutherland, Vicki
AU  - Sutherland V
AD  - Division of the National Toxicology Program, National Institute of Environmental 
      Health Sciences, Research Triangle Park, North Carolina.
FAU - McIntyre, Barry
AU  - McIntyre B
AD  - Division of the National Toxicology Program, National Institute of Environmental 
      Health Sciences, Research Triangle Park, North Carolina.
LA  - eng
GR  - HHSN273201300010C/ES/NIEHS NIH HHS/United States
GR  - HHSN273201300010I/ES/NIEHS NIH HHS/United States
GR  - HHSN273201400027C/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20180219
PL  - United States
TA  - Birth Defects Res
JT  - Birth defects research
JID - 101701004
RN  - 0 (Vinca Alkaloids)
RN  - 543512OBTC (vinpocetine)
SB  - IM
CIN - Birth Defects Res. 2018 Nov 1;110(18):1374-1375. PMID: 30362271
CIN - Birth Defects Res. 2018 Nov 1;110(18):1372-1373. PMID: 30362293
MH  - Abnormalities, Drug-Induced
MH  - Animals
MH  - Dietary Supplements/adverse effects
MH  - Embryonic Development/*drug effects
MH  - Female
MH  - Fetal Development/*drug effects
MH  - Fetal Weight/drug effects
MH  - Fetus/drug effects
MH  - Maternal Exposure
MH  - Pregnancy
MH  - Prenatal Exposure Delayed Effects
MH  - Rabbits
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Vinca Alkaloids/*adverse effects
PMC - PMC5980693
MID - NIHMS938203
OTO - NOTNLM
OT  - dietary supplements
OT  - embryo-fetal development
OT  - embryotoxicity
OT  - fetal malformations
OT  - rabbit
OT  - rat
OT  - vinpocetine
COIS- Declaration of Interest The authors report no declarations of interest.
EDAT- 2018/02/21 06:00
MHDA- 2019/05/07 06:00
PMCR- 2019/06/01
CRDT- 2018/02/21 06:00
PHST- 2017/12/01 00:00 [received]
PHST- 2018/01/16 00:00 [accepted]
PHST- 2018/02/21 06:00 [pubmed]
PHST- 2019/05/07 06:00 [medline]
PHST- 2018/02/21 06:00 [entrez]
PHST- 2019/06/01 00:00 [pmc-release]
AID - 10.1002/bdr2.1207 [doi]
PST - ppublish
SO  - Birth Defects Res. 2018 Jun 1;110(10):883-896. doi: 10.1002/bdr2.1207. Epub 2018 
      Feb 19.